Delta-Fly Pharma, Inc. (TYO:4598)
Japan flag Japan · Delayed Price · Currency is JPY
109.00
-1.00 (-0.91%)
Aug 6, 2026, 3:09 PM JST

Delta-Fly Pharma Financials Overview

Millions JPY. Fiscal year is Apr - Mar.

Revenue & Profits

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Revenue
-----300
Revenue Growth
-----0%
Gross Profit
-----300
Operating Income
-1,605-1,605-1,708-1,403-1,315-961
Net Income
-1,625-1,625-1,721-1,429-1,328-967
Earnings Per Share
-140.37-140.37-195.56-198.72-234.37-178.52
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Investments
1451453381,4178441,268
Total Debt
------
Net Cash (Debt)
1451453381,4178441,268
Net Cash Growth
-57.10%-57.10%-76.15%67.89%-33.44%-39.27%
Net Cash Per Share
12.5312.5338.41197.05148.95234.09

Cash Flow & CapEx

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Operating Cash Flow
-1,557-1,557-1,834-1,279-1,303-940
Capital Expenditures
----1--
Free Cash Flow
-1,557-1,557-1,834-1,280-1,303-940
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingMar '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Gross Margin
-----100.00%
Operating Margin
------320.33%
Pretax Margin
------321.33%
Profit Margin
------322.33%
FCF Margin
------313.33%

Valuation

Fiscal YearCurrentFY 2026FY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
PS Ratio
-----23.12